Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
BPH pharmacotherapy notably affects prostate cancer biomarkers. Recognizing the impact of pharmacotherapy is crucial for achieving an accurate diagnosis of prostate cancer and for planning treatment.
Authors
- Roman Viták (ORCID: https://orcid.org/0009-0009-2895-2541)
- Ladislav Pecen (ORCID: https://orcid.org/0000-0001-9827-3178)
- Radek Kučera (ORCID: https://orcid.org/0000-0002-2739-2302)
- Tomáš Bertók (ORCID: https://orcid.org/0000-0001-7075-2687)
- Jan Tkáč (ORCID: https://orcid.org/0000-0002-0765-7262)
- Michal Jirásko (ORCID: https://orcid.org/0000-0002-4874-7723)
- Andrea Pinkeová (ORCID: https://orcid.org/0009-0008-1321-0580)
- Natalie Bergman
Institutions
- Slovak Academy of Sciences (SK)
- Charles University (CZ)
Publication Details
- Journal
- The Prostate
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1002/pros.24801
- Citations
- 5
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Univerzita Karlova v Praze